Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

ARENA PHARMACEUTICALS INC Form 8-K January 25, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2008

Arena Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

000-31161 (Commission File Number) 23-2908305 (I.R.S. Employer Identification No.)

6166 Nancy Ridge Drive, San Diego, California 92121 (Address of principal executive offices) (Zip Code)

858.453.7200


23-2908305

Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)



23-2908305

Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

In this report, Arena Pharmaceuticals, Arena, we, us and our refer to Arena Pharmaceuticals, Inc. and its wholly owned subsidiaries, unless context otherwise provides.

Item 8.01 Other Events.

On January 25, 2008, we announced that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under our collaboration with Merck to discover drugs for the treatment of atherosclerosis and other disorders. The initiation of this trial does not trigger a milestone payment.

We also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 25, 2008 Arena Pharmaceuticals, Inc.

By: /s/ Jack Lief Jack Lief

President and Chief Executive Officer

2

23-2908305